INCY vs MRNA Stock Comparison
INCY currently leads MRNA in this stock comparison, with AIQ scores of 64 vs 46. The clearest difference is quality, while MRNA has the stronger momentum profile.
What is the main difference between INCY and MRNA?
INCY leads the current stock comparison as Incyte Corporation, with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Incyte Corporation vs Moderna, Inc.
INCY leads
INCY leads by 18 AIQ points, primarily on Quality and Risk Resilience.
Stable: 5 of 6 evidence groups support INCY, and its signal state is cleanly positive.
Incyte Corporation
Moderna, Inc.
The Algovestiq AIQ Score currently favors INCY over MRNA, 64 versus 46 as of Oct 21, 2026. INCY's advantage is driven primarily by stronger quality and risk resilience, while MRNA holds the stronger momentum profile. INCY also shows the weaker technical structure relative to its 50-day moving average. 5 of 6 covered evidence groups favor INCY today, and the comparison is rated Stable on stability. INCY lead: Stable — the AIQ differential has held near 18 points over 30 sessions.
Compare Incyte Corporation and Moderna, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare INCY and MRNA against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality90 vs 27INCY +63
- Momentum40 vs 78MRNA +38
- Risk Resilience74 vs 54INCY +20
- Value52 vs 34INCY +18
5 of 6 evidence groups favor INCY. INCY’s edge is concentrated in quality and risk resilience; MRNA keeps a meaningful momentum edge.
What changed since the last close
Latest scored session 2026-10-20, compared against the prior scored session 2026-10-19.
Largest factor move: Momentum +10
New signals
- MACD Bullish Crossover — bullish, momentum, short horizon
Largest factor move: Momentum +9
New signals
- BB Upper Band Breach — bearish, volatility, short horizon
INCY's lead widened by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — INCY and MRNA both carry a full feed there.
The central trade-off
INCY (Incyte Corporation): the stronger current systematic profile, led by quality and risk resilience.
MRNA (Moderna, Inc.): the counter-case, on momentum, technicals — but at materially higher volatility, 87.1% against 25.4%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
INCYINCY on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
INCYINCY on combined revenue and EPS growth.
Value
INCYINCY on the peer-relative Value factor, by 18 points.
Momentum
MRNAMRNA on the Momentum factor, by 38 points.
Lower downside
INCYINCY on Risk Resilience, by 20 points.
Analyst upside
INCYINCY on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | INCY | MRNA | Note |
|---|---|---|---|
| Implied upside to target | +9.9% | -61.1% | INCY has more room |
| Target dispersion | +53.7% | +230.1% | Lower is tighter analyst agreement |
| Consensus | Hold | Hold | Context, not a primary driver |
| Analysts covering | 15 | 10 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
5 of 6 covered evidence groups favor INCY. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | INCY | 64 vs 46 |
| Fundamentals | INCY | revenue growth 31.5% vs -62.7%; EPS growth 92.1% vs 42.4%; TTM ROE 29.7% vs -39.2%; gross margin 92.6% vs -12.6%; operating margin 31.6% vs -149% |
| Valuation | INCY | Value 52 vs 34 |
| Technicals | MRNA | Price vs 50-day -6.7% vs 51.8%; vs 200-day 8.3% vs 204.7% |
| Risk Resilience | INCY | Risk Resilience 74 vs 54 |
| Analyst expectations | INCY | Target upside 9.9% vs -61.1% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of INCY and MRNA and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 18 points. (supports the conclusion holding)
- 5 of 6 covered evidence groups point the same way. (supports the conclusion holding)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader's signal state is cleanly positive. (supports the conclusion holding)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on INCY.
How the comparison changed
120 daily snapshots · Jun 21 – Oct 20INCY lead: Stable — the AIQ differential has held near 18 points over 30 sessions.
- Today
- INCY +18
- 64 vs 46
- 7 sessions ago
- INCY +15
- 61 vs 46
- 30 sessions ago
- INCY +16
- 64 vs 48
- 90 sessions ago
- INCY +19
- 65 vs 46
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
2 bullish / 0 bearish
No signal that the other name lacks.
5 bullish / 1 bearish / 1 neutral, conflicted
Only MRNA
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (7.39%)
- BB Upper Band Breach — bearish, volatility, short horizon
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- 52-Week High Proximity — bullish, risk, long horizon (0.0%)
- Uptrend Structure Active — bullish, trend, long horizon
Both carry 2 more signals that do not separate them: Golden Cross Active, MACD Bullish Crossover.
MRNA is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price is down while the AIQ Score moved up 3 points over the same session — price and model disagree (price -2.72%, AIQ +3 points).
Price and the AIQ Score both moved up over the latest session (price +1.54%, AIQ +2 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1MRNA closes the Quality gap — currently 63 points behind, the largest single contributor to INCY's edge.
- 2MRNA's BB Upper Band Breach resolves — a bearish volatility rule currently active against it.
- 3INCY's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
INCY leads on balance| Metric | INCY | MRNA |
|---|---|---|
| Revenue growth (YoY) | 31.5% | -62.7% |
| EPS growth (YoY) | 92.1% | 42.4% |
| Gross margin | 92.6% | -12.6% |
| Operating margin | 31.6% | -149% |
| Return on equity (TTM) | 29.7% | -39.2% |
| Debt to equity | 0.01 | 0.19 |
Performance
MRNA leads 6 of 6 windows| Metric | INCY | MRNA |
|---|---|---|
| 1 week (5 sessions) | 7.4% | 11.9% |
| 1 month (20 sessions) | -8.1% | 32.6% |
| 3 months (63 sessions) | 0.7% | 280.9% |
| 6 months (126 sessions) | 21.2% | 334% |
| Year to date | 18.1% | 667% |
| 1 year (252 sessions) | 33.6% | 787.7% |
Technicals
MRNA has the stronger structure| Metric | INCY | MRNA |
|---|---|---|
| RSI (14) | 39.5 | 66.8 |
| ADX (14) | 25.2 | 61.9 |
| Price vs 50-day | -6.7% | 51.8% |
| Price vs 200-day | 8.3% | 204.7% |
| Volatility (1M, annualized) | 25.4% | 87.1% |
Risk
INCY is the more resilient| Metric | INCY | MRNA |
|---|---|---|
| Beta | 0.4 | 2.03 |
| Sharpe ratio | 0.91 | 1.69 |
| Sortino ratio | 1.55 | 6.82 |
| Max drawdown | -18.3% | -34.2% |
| Current drawdown | -10.3% | 0% |
| Annualized volatility | 33.4% | 193.8% |
| Value at risk (95%) | -2.7% | -6.9% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, INCY or MRNA?
On the Algovestiq AIQ Score, INCY is the stronger of the two as of Oct 21, 2026, scoring 64 against MRNA's 46. The edge comes from quality and risk resilience. MRNA is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is INCY or MRNA the better buy right now?
INCY carries the stronger systematic profile as of Oct 21, 2026, and the comparison is rated Stable — 5 of 6 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor INCY over MRNA?
The composite weights Quality, Value, Momentum and Risk Resilience. INCY leads Quality by 63 points; MRNA leads Momentum by 38 points; INCY leads Risk Resilience by 20 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, INCY or MRNA?
Analyst price targets imply +9.9% upside for INCY and -61.1% for MRNA, so the Street currently favors INCY. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, INCY or MRNA?
INCY is the better-valued of the two on the peer-relative Value factor. INCY on the peer-relative Value factor, by 18 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, INCY or MRNA?
INCY on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, INCY or MRNA?
MRNA on the Momentum factor, by 38 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, INCY or MRNA?
INCY is the more resilient of the two, so the other name carries the higher downside risk. INCY on Risk Resilience, by 20 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is INCY more profitable than MRNA?
INCY leads on the comparable margin measures — gross margin 92.6% vs -12.6%; operating margin 31.6% vs -149%; ttm roe 29.7% vs -39.2%.
Is INCY's lead over MRNA getting stronger or weaker?
INCY lead: Stable — the AIQ differential has held near 18 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-21 and 2026-10-20. The lead has not changed hands in that window.
What would change the INCY vs MRNA verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: MRNA closes the Quality gap — currently 63 points behind, the largest single contributor to INCY's edge; MRNA's BB Upper Band Breach resolves — a bearish volatility rule currently active against it; INCY's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about INCY and MRNA?
INCY: 2 bullish / 0 bearish. MRNA: 5 bullish / 1 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on INCY is Golden Cross Active (bullish, long horizon). On MRNA it is Golden Cross Active (bullish, long horizon).
Compare INCY and MRNA with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.